PD-1 inhibitors monotherapy in hepatocellular carcinoma: meta-analysis and systematic review

ConclusionsPembrolizumab and nivolumab are the only checkpoint inhibitors with data in HCC. Meta-analysis of their effectiveness discloses rates not dissimilar to other systemic therapies available for this disease. Of interest also are the observed long responses in a sub-set of responders. Further development is clearly warranted.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research